Elevation Oncology, Inc.

General Information
Business:

We are a precision oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. Our vision is to elevate precision medicine to the forefront of every cancer treatment journey, as we believe that each patient living with cancer deserves the opportunity to benefit from a genomically-driven treatment decision. We utilize our deep expertise in developing drugs for rare, genomically-defined patient populations and strategic collaborations with our diagnostic collaborators to work towards a future where each tumor’s unique genomic test result can be matched with a purpose-built precision medicine.

(Note: Elevation Oncology priced its IPO on June 24, 2021, in line with the terms in its prospectus: 6.25 million shares at $16 – the mid-point of its $15-to-$17 range – to raise $100 million.)

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 8
Founded: 2019
Contact Information
Address 888 Seventh Ave., 12th Floor, New York, New York 10106, USA
Phone Number (716) 371-1125
Web Address
View Prospectus: Elevation Oncology, Inc.
Financial Information
Market Cap $365.1mil
Revenues $0 mil (last 12 months)
Net Income $-20.4 mil (last 12 months)
IPO Profile
Symbol ELEV
Exchange NASDAQ
Shares (millions): 6.3
Price range $16.00 - $16.00
Est. $ Volume $100.0 mil
Manager / Joint Managers J.P. Morgan/ Cowen/ SVB Leerink ​ ​
CO-Managers Wedbush PacGrow ​ ​
Expected To Trade: 6/25/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change